Q-omics provides the consensus-scored POMZP3 profile across patient tissues and cancer cell-line models. POMZP3 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, POMZP3 is differentially expressed in 7, with the highest sampling consensus in LIHC. Additionally, POMZP3 RNA expression shows 12,051 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KICH, LIHC, and LSCC as cancer lineages where POMZP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POMZP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POMZP3 survival associations across molecular data types. POMZP3 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POMZP3 RNA expression–survival associations across cancer types. High POMZP3 expression shows unfavorable associations in KICH, LIHC and BLCA, but favorable associations in OV, LUSC and CESC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KICH as the clearest survival context for POMZP3 RNA expression.
This table summarizes POMZP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for POMZP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POMZP3 shows lower tumor expression in KICH and UCEC and higher tumor expression in LIHC, HNSC, CHOL and KIRC. The LIHC box plot shows higher POMZP3 RNA expression in tumor versus normal tissue (log2 FC = +0.921, t-test p < 0.001).
This table shows molecular features associated with POMZP3 in patient tissues and cancer cell lines. In patient samples, POMZP3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, POMZP3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in CNS and BREAST.
